DK1940465T3 - Ny anvendelse af anti-IL-1beta-antistoffer - Google Patents

Ny anvendelse af anti-IL-1beta-antistoffer

Info

Publication number: DK1940465T3
Authority: DK; Denmark
Prior art keywords: new use; 1beta antibodies; 1beta; antibodies; new
Prior art date: 2005-10-26

Application number

DK06826560.2T

Other languages

English (en)

Inventor

Phil Lowe

Thomas Jung

Hermann Gram

Timothy Wright

Trevor Mundel

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-26

Filing date

2006-10-24

Publication date

2012-10-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37806690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1940465(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-10-24 Application filed by Novartis Ag filed Critical Novartis Ag

2012-10-22 Application granted granted Critical

2012-10-22 Publication of DK1940465T3 publication Critical patent/DK1940465T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Mycology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Zoology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)

DK06826560.2T 2005-10-26 2006-10-24 Ny anvendelse af anti-IL-1beta-antistoffer DK1940465T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US73043505P	2005-10-26	2005-10-26
US74212505P	2005-12-02	2005-12-02
PCT/US2006/041479 WO2007050607A2 (en)	2005-10-26	2006-10-24	Novel use of il-1beta compounds

Publications (1)

Publication Number	Publication Date
DK1940465T3 true DK1940465T3 (da)	2012-10-22

Family

ID=37806690

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK14191582.7T DK2848258T3 (da)	2005-10-26	2006-10-24	Behandling af familiær middelhavsfeber med anti-IL-1beta-antistoffer
DK06826560.2T DK1940465T3 (da)	2005-10-26	2006-10-24	Ny anvendelse af anti-IL-1beta-antistoffer

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK14191582.7T DK2848258T3 (da)	2005-10-26	2006-10-24	Behandling af familiær middelhavsfeber med anti-IL-1beta-antistoffer

Country Status (29)

Country	Link
US (8)	US8105587B2 (da)
EP (5)	EP1940465B1 (da)
JP (4)	JP2009513645A (da)
KR (3)	KR101518064B1 (da)
CN (2)	CN101291693B (da)
AU (1)	AU2006306280B2 (da)
BR (1)	BRPI0617830B8 (da)
CA (3)	CA2626214C (da)
CY (4)	CY1113378T1 (da)
DK (2)	DK2848258T3 (da)
ES (3)	ES2662420T3 (da)
HK (3)	HK1121041A1 (da)
HU (2)	HUE036973T2 (da)
IL (4)	IL190545A (da)
JO (2)	JO2826B1 (da)
LT (3)	LT2848258T (da)
LU (2)	LU92326I2 (da)
MA (1)	MA29919B1 (da)
NO (2)	NO345888B1 (da)
NZ (1)	NZ567222A (da)
PH (2)	PH12013501287A1 (da)
PL (2)	PL2848258T3 (da)
PT (2)	PT1940465E (da)
RU (2)	RU2468817C2 (da)
SI (2)	SI2848258T1 (da)
TN (1)	TNSN08189A1 (da)
TR (1)	TR201802449T4 (da)
TW (3)	TWI537003B (da)
WO (1)	WO2007050607A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO345888B1 (no)	2005-10-26	2021-09-27	Novartis Ag	Medikament til bruk ved behandling av familiær Middelhavsfeber omfattende et humant IL-1-beta bindende antistoff og en farmasøytisk sammensetning omfattende antistoffet til bruk ved behandling av familiær Middelhavsfeber.
EP2152308A1 (en)	2007-05-29	2010-02-17	Novartis Ag	New indications for anti- il-i-beta therapy
AU2012203932B2 (en) *	2007-05-29	2014-04-24	Novartis Ag	New indications for anti-IL-I-beta therapy
PL2293816T3 (pl) *	2008-06-06	2013-04-30	Xoma Us Llc	Sposoby leczenia reumatoidalnego zapalenia stawów
EP2196476A1 (en)	2008-12-10	2010-06-16	Novartis Ag	Antibody formulation
WO2011032119A1 (en)	2009-09-14	2011-03-17	The Regents Of The University Of Colorado	Modulation of yeast-based immunotherapy products and responses
IN2012DN02634A (da) *	2009-10-15	2015-09-04	Abbvie Inc
AU2011252883B2 (en) *	2010-05-14	2015-09-10	Abbvie Inc.	IL-1 binding proteins
SG10201604699VA (en) *	2010-12-21	2016-07-28	Abbvie Inc	Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
JP2014517279A (ja)	2011-05-10	2014-07-17	ネステクソシエテアノニム	個別治療管理のための疾患活動性プロファイリングの方法
WO2017153936A1 (en)	2016-03-10	2017-09-14	Novartis Ag	Chemically modified messenger rna's
KR20200009095A (ko)	2017-05-31	2020-01-29	프로메테우스 바이오사이언시즈, 인크.	크론병 환자에서 점막 치유를 평가하는 방법
UY37758A (es)	2017-06-12	2019-01-31	Novartis Ag	Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
WO2018235056A1 (en)	2017-06-22	2018-12-27	Novartis Ag	Il-1beta binding antibodies for use in treating cancer
TW201946652A (zh)	2018-05-09	2019-12-16	瑞士商諾華公司	康納單抗(canakinumab)之用途
SG11202104699TA (en)	2018-12-21	2021-07-29	Novartis Ag	Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
WO2020128637A1 (en)	2018-12-21	2020-06-25	Novartis Ag	Use of il-1 binding antibodies in the treatment of a msi-h cancer
EP3897613A1 (en)	2018-12-21	2021-10-27	Novartis AG	Use of il-1beta binding antibodies
JP2022514087A (ja)	2018-12-21	2022-02-09	ノバルティスアーゲー	ＩＬ－１β結合抗体の使用
TWI793503B (zh) *	2020-01-20	2023-02-21	美商美國禮來大藥廠	抗IL-1β抗體
US20250099548A1 (en) *	2022-01-10	2025-03-27	Gi Innovation, Inc.	Pharmaceutical composition for preventing or treating degenerative brain diseases, containing glucagon-like peptide-1 and interleukin-1 receptor antagonist

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
EP0710719B1 (en)	1990-01-12	2007-03-14	Amgen Fremont Inc.	Generation of xenogeneic antibodies
US5350683A (en) *	1990-06-05	1994-09-27	Immunex Corporation	DNA encoding type II interleukin-1 receptors
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es)	1990-08-29	2006-02-16	Genpharm International, Inc.	Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
WO1995001997A1 (en) *	1993-07-09	1995-01-19	Smithkline Beecham Corporation	RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
WO1995016353A1 (en)	1993-12-14	1995-06-22	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Systemic gene treatment of connective tissue diseases
AU735648B2 (en)	1996-07-12	2001-07-12	Ariad Pharmaceuticals, Inc.	Materials and method for treating or preventing pathogenic fungal infection
US6294170B1 (en) *	1997-08-08	2001-09-25	Amgen Inc.	Composition and method for treating inflammatory diseases
IL144492A0 (en)	1999-02-10	2002-05-23	Interleukin Genetics Inc	Therapeutics and diagnostics based on an il-1b mutation
PL352944A1 (en) *	1999-07-16	2003-09-22	Leo Pharma	Aminobenzophenones as inhibitors of il-1beta and tnf-alpha
ATE264863T1 (de)	1999-08-24	2004-05-15	Ariad Gene Therapeutics Inc	28-epirapaloge
GB0001448D0 (en) *	2000-01-21	2000-03-08	Novartis Ag	Organic compounds
EP1282435A2 (en) *	2000-05-12	2003-02-12	Immunex Corporation	Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) *	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
KR20080014934A (ko)	2000-11-07	2008-02-14	노파르티스 아게	단백질 키나제 ｃ 억제제로서의 인돌릴말레이미드 유도체
EP1423432A4 (en) *	2001-07-26	2006-01-11	Lilly Co Eli	ANTIBODIES TO INTERLEUKIN 1 BETA (IL-1BETA)
EP1450837A4 (en) *	2001-08-07	2006-01-04	Immunex Corp	INTERLEUKIN-1 RECEPTORS IN THE TREATMENT OF DISEASES
EP1459435B1 (en)	2001-12-01	2012-05-02	Iskra Wind Turbines Ltd.	Synchronous alternating current generator incorporating a braking mechansim
KR200268109Y1 (ko)	2001-12-06	2002-03-15	김정훈	편평형 무정류자 진동모터
EP2407473A3 (en)	2002-02-01	2012-03-21	ARIAD Pharmaceuticals, Inc	Method for producing phosphorus-containing compounds
MXPA04007124A (es)	2002-02-01	2004-10-29	Omeros Corp	Composiciones y metodos para la inhibicion sistemica de la degradacion del cartilago.
MXPA04007694A (es) *	2002-02-11	2004-11-10	Arkion Life Sciences Llc	Factor inhibidor de citosina purificada.
PE20040079A1 (es)	2002-04-03	2004-04-19	Novartis Ag	Derivados de indolilmaleimida
BR0317099A (pt)	2002-12-09	2005-10-25	Boardd Of Regents Of The Unive	Método in vitro para inibir a função e/ou proliferação de uma janus tirosina quinase 3, método de teste in vitro para auxiliar na identificação de substâncias que são úteis como imunossupressores terapêuticos, método in vitro para auxiliar na identificação de um novo medicamento imunossupressor, método in vitro para inibir a função e/ou proliferação de uma célula expressando a janus tirosina quinase 3, uso de pelo menos um composto, composto quìmico isolado ou purificado e composição farmacêutica
JP4538461B2 (ja) *	2003-01-24	2010-09-08	アプライドモレキュラーエボリューション，インコーポレイテッド	ヒトＩＬ−１βアンタゴニスト
GB0303337D0 (en) *	2003-02-13	2003-03-19	Celltech R&D Ltd	Biological products
AU2005249503B2 (en) *	2003-11-10	2011-08-25	Vertex Pharmaceuticals Incorporated	ICE inhibitors for the treatment of autoinflammatory diseases
WO2005047906A1 (en)	2003-11-10	2005-05-26	Vertex Pharmaceuticals Incorporated	Methods for monitoring il-18
PT1704145E (pt)	2004-01-12	2012-09-04	Ym Biosciences Australia Pty	Inibidores de quinase seletivos
US7615212B2 (en) *	2004-02-26	2009-11-10	Baylor Research Institute	Compositions and methods for the systemic treatment of arthritis
AU2005249570B2 (en) *	2004-06-04	2011-06-16	Regeneron Pharmaceuticals, Inc.	Methods of using IL-1 antagonists to treat autoinflammatory disease
US8003779B2 (en)	2005-01-20	2011-08-23	University Of Rochester	Compositions and methods for studying and treating inflammatory diseases and disorders
ES2546484T3 (es)	2005-03-18	2015-09-24	Dsm Ip Assets B.V.	Producción de carotenoides en levadura y hongos oleaginosos
SI2322552T1 (sl)	2005-06-21	2016-07-29	Xoma (Us) Llc	IL-1beta vezavna protitelesa in njihovi fragmenti
NO345888B1 (no) *	2005-10-26	2021-09-27	Novartis Ag	Medikament til bruk ved behandling av familiær Middelhavsfeber omfattende et humant IL-1-beta bindende antistoff og en farmasøytisk sammensetning omfattende antistoffet til bruk ved behandling av familiær Middelhavsfeber.

2006
- 2006-10-24 NO NO20200810A patent/NO345888B1/no unknown
- 2006-10-24 WO PCT/US2006/041479 patent/WO2007050607A2/en active Application Filing
- 2006-10-24 EP EP06826560A patent/EP1940465B1/en active Active
- 2006-10-24 EP EP17199544.2A patent/EP3332807B1/en active Active
- 2006-10-24 PL PL14191582T patent/PL2848258T3/pl unknown
- 2006-10-24 CA CA2626214A patent/CA2626214C/en active Active
- 2006-10-24 DK DK14191582.7T patent/DK2848258T3/da active
- 2006-10-24 KR KR1020087009981A patent/KR101518064B1/ko active Active
- 2006-10-24 AU AU2006306280A patent/AU2006306280B2/en active Active
- 2006-10-24 CN CN200680039395XA patent/CN101291693B/zh active Active
- 2006-10-24 JP JP2008537878A patent/JP2009513645A/ja not_active Withdrawn
- 2006-10-24 LT LTEP14191582.7T patent/LT2848258T/lt unknown
- 2006-10-24 ES ES14191582.7T patent/ES2662420T3/es active Active
- 2006-10-24 NZ NZ567222A patent/NZ567222A/en not_active IP Right Cessation
- 2006-10-24 KR KR1020177008682A patent/KR20170038131A/ko not_active Ceased
- 2006-10-24 EP EP14191582.7A patent/EP2848258B1/en active Active
- 2006-10-24 EP EP23155348.8A patent/EP4218815A3/en active Pending
- 2006-10-24 BR BRPI0617830A patent/BRPI0617830B8/pt active IP Right Grant
- 2006-10-24 HU HUE14191582A patent/HUE036973T2/hu unknown
- 2006-10-24 DK DK06826560.2T patent/DK1940465T3/da active
- 2006-10-24 US US12/090,490 patent/US8105587B2/en active Active
- 2006-10-24 CA CA2898369A patent/CA2898369C/en active Active
- 2006-10-24 PL PL06826560T patent/PL1940465T3/pl unknown
- 2006-10-24 ES ES06826560T patent/ES2389110T3/es active Active
- 2006-10-24 KR KR1020147035512A patent/KR101749388B1/ko active Active
- 2006-10-24 ES ES17199544T patent/ES2944067T3/es active Active
- 2006-10-24 SI SI200632245T patent/SI2848258T1/en unknown
- 2006-10-24 PT PT06826560T patent/PT1940465E/pt unknown
- 2006-10-24 TR TR2018/02449T patent/TR201802449T4/tr unknown
- 2006-10-24 EP EP10181100A patent/EP2332577A1/en not_active Withdrawn
- 2006-10-24 CN CN2012102904088A patent/CN102861332A/zh active Pending
- 2006-10-24 RU RU2008120625/15A patent/RU2468817C2/ru active
- 2006-10-24 PT PT141915827T patent/PT2848258T/pt unknown
- 2006-10-24 SI SI200631412T patent/SI1940465T1/sl unknown
- 2006-10-24 CA CA2963828A patent/CA2963828A1/en not_active Abandoned
- 2006-10-25 TW TW101132057A patent/TWI537003B/zh active
- 2006-10-25 TW TW095139438A patent/TWI388335B/zh active
- 2006-10-25 TW TW105103583A patent/TWI626056B/zh active
- 2006-10-29 JO JO2006387A patent/JO2826B1/en active
2008
- 2008-03-31 IL IL190545A patent/IL190545A/en active IP Right Grant
- 2008-04-23 MA MA30863A patent/MA29919B1/fr unknown
- 2008-04-25 TN TNP2008000189A patent/TNSN08189A1/en unknown
- 2008-05-23 NO NO20082344A patent/NO345140B1/no unknown
2009
- 2009-01-07 HK HK09100171.2A patent/HK1121041A1/xx unknown
2011
- 2011-10-27 US US13/283,165 patent/US8409576B2/en active Active
2012
- 2012-08-06 RU RU2012133522/15A patent/RU2571563C2/ru active
- 2012-09-24 CY CY20121100867T patent/CY1113378T1/el unknown
2013
- 2013-02-26 US US13/777,609 patent/US20130171167A1/en not_active Abandoned
- 2013-03-27 JP JP2013066205A patent/JP6061747B2/ja active Active
- 2013-06-18 PH PH12013501287A patent/PH12013501287A1/en unknown
- 2013-12-05 LU LU92326C patent/LU92326I2/fr unknown
- 2013-12-06 LT LTPA2013026C patent/LTC1940465I2/lt unknown
- 2013-12-13 CY CY2013046C patent/CY2013046I1/el unknown
2014
- 2014-03-16 JO JOP/2014/0120A patent/JOP20140120B1/ar active
2015
- 2015-06-03 HK HK15105300.7A patent/HK1204767A1/xx unknown
- 2015-07-28 US US14/810,556 patent/US9649377B2/en active Active
- 2015-10-02 JP JP2015196708A patent/JP6286403B2/ja active Active
2016
- 2016-05-02 IL IL245387A patent/IL245387B/en active IP Right Grant
2017
- 2017-04-11 US US15/484,459 patent/US20170218063A1/en not_active Abandoned
- 2017-08-04 JP JP2017151327A patent/JP2017206552A/ja active Pending
2018
- 2018-03-12 CY CY20181100301T patent/CY1120018T1/el unknown
- 2018-03-12 US US15/918,136 patent/US20180201674A1/en not_active Abandoned
- 2018-04-26 IL IL258983A patent/IL258983B/en active IP Right Grant
- 2018-06-11 LU LU00078C patent/LUC00078I2/fr unknown
- 2018-06-11 HU HUS1800025C patent/HUS1800025I1/hu unknown
- 2018-06-12 CY CY2018018C patent/CY2018018I1/el unknown
- 2018-06-12 LT LTPA2018506C patent/LTC2848258I2/lt unknown
- 2018-09-10 HK HK18111596A patent/HK1252316A1/zh unknown
2020
- 2020-06-19 US US16/906,118 patent/US20210147533A1/en not_active Abandoned
- 2020-06-23 PH PH12020500559A patent/PH12020500559A1/en unknown
- 2020-09-16 IL IL277406A patent/IL277406A/en unknown
2023
- 2023-02-28 US US18/175,849 patent/US20240083997A1/en active Pending

Also Published As

Publication number	Publication date
CY2018018I2 (el)	2018-12-12
KR20080059598A (ko)	2008-06-30
IL190545A (en)	2016-09-29
IL258983A (en)	2018-06-28
PH12020500559A1 (en)	2021-06-14
JP2013166757A (ja)	2013-08-29
LU92326I9 (da)	2019-01-16
JP6061747B2 (ja)	2017-01-18
SI2848258T1 (en)	2018-03-30
KR20170038131A (ko)	2017-04-05
KR101749388B1 (ko)	2017-06-20
CA2626214C (en)	2016-06-21
LTC2848258I2 (lt)	2019-08-12
EP4218815A3 (en)	2024-03-27
ES2389110T3 (es)	2012-10-23
LT2848258T (lt)	2018-02-26
TR201802449T4 (tr)	2018-03-21
LU92326I2 (fr)	2014-02-05
RU2008120625A (ru)	2010-01-20
TWI388335B (zh)	2013-03-11
PH12013501287B1 (en)	2016-02-01
NO345140B1 (no)	2020-10-12
MA29919B1 (fr)	2008-11-03
CY2013046I2 (el)	2015-11-04
TWI537003B (zh)	2016-06-11
CA2626214A1 (en)	2007-05-03
LTC1940465I2 (lt)	2017-12-11
IL258983B (en)	2020-10-29
JP2017206552A (ja)	2017-11-24
EP3332807A3 (en)	2018-06-20
EP1940465B1 (en)	2012-08-01
TWI626056B (zh)	2018-06-11
CA2898369A1 (en)	2007-05-03
EP2332577A1 (en)	2011-06-15
DK2848258T3 (da)	2018-03-19
AU2006306280A1 (en)	2007-05-03
HK1252316A1 (zh)	2019-05-24
KR20150013834A (ko)	2015-02-05
HUS1800025I1 (hu)	2018-07-30
IL245387A0 (en)	2016-06-30
CY1120018T1 (el)	2018-12-12
PL2848258T3 (pl)	2018-06-29
EP2848258A1 (en)	2015-03-18
US20120039910A1 (en)	2012-02-16
PT1940465E (pt)	2012-10-03
US20150322148A1 (en)	2015-11-12
WO2007050607A3 (en)	2007-06-28
JP2009513645A (ja)	2009-04-02
EP3332807B1 (en)	2023-02-22
US9649377B2 (en)	2017-05-16
HK1121041A1 (en)	2009-04-17
TW200803898A (en)	2008-01-16
CN101291693A (zh)	2008-10-22
PT2848258T (pt)	2018-03-20
BRPI0617830B1 (pt)	2020-10-20
US8105587B2 (en)	2012-01-31
CY2018018I1 (el)	2018-12-12
KR101518064B1 (ko)	2015-05-06
RU2012133522A (ru)	2014-02-20
SI1940465T1 (sl)	2012-10-30
LTPA2018506I1 (lt)	2018-06-25
JP2016020377A (ja)	2016-02-04
ES2944067T3 (es)	2023-06-19
RU2468817C2 (ru)	2012-12-10
EP2848258B1 (en)	2017-12-13
IL277406A (en)	2020-11-30
TW201302220A (zh)	2013-01-16
CA2898369C (en)	2017-06-20
ES2662420T3 (es)	2018-04-06
CA2963828A1 (en)	2007-05-03
TNSN08189A1 (en)	2009-10-30
JO2826B1 (en)	2014-09-15
LUC00078I2 (fr)	2018-08-14
NZ567222A (en)	2011-07-29
CY1113378T1 (el)	2015-11-04
JP6286403B2 (ja)	2018-02-28
BRPI0617830A2 (pt)	2011-08-09
CN102861332A (zh)	2013-01-09
BRPI0617830B8 (pt)	2021-05-25
EP3332807A2 (en)	2018-06-13
HK1204767A1 (zh)	2015-12-04
US20210147533A1 (en)	2021-05-20
US20240083997A1 (en)	2024-03-14
PH12013501287A1 (en)	2016-02-01
US20170218063A1 (en)	2017-08-03
TW201617097A (zh)	2016-05-16
IL245387B (en)	2019-09-26
IL190545A0 (en)	2008-11-03
CY2013046I1 (el)	2015-11-04
WO2007050607A2 (en)	2007-05-03
NO20082344L (no)	2008-07-22
US20080286266A1 (en)	2008-11-20
EP1940465A2 (en)	2008-07-09
CN101291693B (zh)	2012-10-03
EP4218815A2 (en)	2023-08-02
AU2006306280B2 (en)	2010-06-17
US20130171167A1 (en)	2013-07-04
NO20200810A1 (no)	2008-07-22
JOP20140120B1 (ar)	2021-08-17
HUE036973T2 (hu)	2018-08-28
NO345888B1 (no)	2021-09-27
PL1940465T3 (pl)	2013-01-31
US8409576B2 (en)	2013-04-02
RU2571563C2 (ru)	2015-12-20
US20180201674A1 (en)	2018-07-19

Publication	Publication Date	Title
DK1940465T3 (da)	2012-10-22	Ny anvendelse af anti-IL-1beta-antistoffer
NO20190202A1 (no)	2008-05-19	Anvendelse av anti-CGRP antagonist antistoff
DK1802579T3 (da)	2014-01-20	Derivater af 3-arylaminopyridin
NO20071430L (no)	2007-05-15	Anti-OX4OL antistoffer
DK1730476T3 (da)	2021-06-21	Simplificeret måling af fluidegenskaber
DK1778618T3 (da)	2014-03-10	Syntese af triethylentetraminer
DK1720866T3 (da)	2011-11-21	Fremgangsmåde
DK1587542T3 (da)	2012-07-30	Anvendelse af anti-CD100-antistoffer
DK1964852T3 (da)	2013-07-08	Anti-ilt7-antistof
NO20076607L (no)	2008-02-27	TWEAK - bindende antistoff
DE602005027428D1 (de)	2011-05-26	Toner
DK1981859T3 (da)	2013-01-21	Fremstilling af delmopinol
DE602004019389D1 (de)	2009-03-26	Toner
DE602006003681D1 (de)	2009-01-02	Toner
PT2364729E (pt)	2014-09-01	Anticorpos antagonísticos de il-17
DK1737891T3 (da)	2013-03-25	Anti-p-selectin-antistoffer
ATE501174T1 (de)	2011-03-15	Antikörper gegen madcam
DE602006020221D1 (de)	2011-04-07	Toner
ATE483732T1 (de)	2010-10-15	Madcam-antikörper
DK1917227T3 (da)	2013-05-27	Krystalformer af astaxanthin
EP1906944A4 (en)	2010-08-04	SKI ANDRIN-B-PREPARATION
DK2228656T3 (da)	2014-02-03	Kvantificering af allergener
NO20043305D0 (no)	2004-08-09	Preparation of lodixanol
NO20055643D0 (no)	2005-11-29	Preparation of lodixanol
DK1763520T3 (da)	2009-02-09	Anvendelse af trisubstituerede benzopyranoner